Koorosh Haghayeghi

Koorosh Haghayeghi

Auto-generated profile, based on publicly available information

Koorosh Haghayeghi

Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, Warren Alpert Medical School of Brown University, Providence, RI, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2021 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
KHKoorosh Haghayeghi
Koorosh Haghayeghi
SLShaolei Lu
Shaolei Lu
AMAndres Matoso
Andres Matoso
SSStephen F. Schiff
Stephen F. Schiff
CMCatrina Mueller-Leonhard
Catrina Mueller-Leonhard
AAAli Amin
Ali Amin

21 June 2020 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
KHKoorosh Haghayeghi
Koorosh Haghayeghi
MNMehran Najibi
Mehran Najibi
HWHai Wang
Hai Wang
LDLinda Donegan
Linda Donegan
YWYihong Wang
Yihong Wang

29 March 2020 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
KHKoorosh Haghayeghi
Koorosh Haghayeghi
JDJoseph A. Dicomo
Joseph A. Dicomo
DEDavid Edmonson
David Edmonson
NBNatalie Banet
Natalie Banet

21 January 2020 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
KHKoorosh Haghayeghi
Koorosh Haghayeghi
GTGladys Telang
Gladys Telang
SCSonja Mbbs Chen
Sonja Mbbs Chen
JBJack Bevivino
Jack Bevivino
SMShamlal Mbbs Mangray
Shamlal Mbbs Mangray
LRLeslie Robinson-Bostom
Leslie Robinson-Bostom
Hybrid peripheral nerve sheath tumors (PNSTs) are rare benign composite neoplasms demonstrating features of multiple endogenous nerve sheath cell types. Hybrid PNSTs with granular cell components are exceedingly rare. Only a handful number of hybrid PNSTs composed of granular cell tumor and perineurioma have been described to date. We present a rare hybrid of perineurioma and granular cell tumor and review the literature.

24 August 2022 in Cureus
Verified
Journal Article
Open access
MAMohannad A Almikhlafi
Mohannad A Almikhlafi
KHKoorosh Haghayeghi
Koorosh Haghayeghi
AGAlice Gardner
Alice Gardner
Asthma is a chronic disease characterized by chronic inflammation, reversible airway obstruction, airway hyperresponsiveness (AHR), and airway remodeling. One of the important features of asthma is airway remodeling, which plays a central role in airflow limitation. Airway remodeling involves numerous changes in the bronchial walls, including airway smooth muscle (ASM) cell hypertrophy and hyperplasia. Studies have shown that ASM hyperplasia in asthma is mediated by the increased production of mitogens. Endothelin-1 (ET-1) has been shown to induce proliferation and function as a co-mitogen in vascular and ASM. In patients with asthma, plasma and bronchoalveolar lavage fluid have been shown to have elevated ET-1 levels, which have been linked to airway remodeling and airflow obstruction in severe asthma. This study investigates the role of ET-1 in proliferation, the receptor subtype mediating its effect, and the signaling pathway. Normal and asthmatic bronchial airway smooth muscle (BASM) cells were seeded into 5 × 103 cells/well. Cell proliferation was assayed using 5-bromo-2’-deoxyuridine (BrdU) incorporation. Confluent cells were treated with different concentrations of ET-1 in the presence or absence of the epidermal growth factor (EGF). Signaling pathways were explored using pretreatment of BASM with antagonists 15 minutes before ET-1/EGF stimulation. In asthmatic BASM, ET-1 (0.1 nM) functions as a co-mitogen in the presence of EGF (10 nM), showing a significantly greater effect on asthmatic BASM proliferation compared with normal BASM. The ETA receptor antagonist BQ-123 (10-1,000 nM) significantly reduced the proliferative effect of ET-1/EGF on asthmatic BASM more than normal BASM. Moreover, the effect of ETB antagonist BQ-788 (1,000 nM) or pretreatment with the ETB agonist S6C (1-10 nM) followed by co-treatment with EGF in asthmatic BASM showed a small but significant decrease when pretreated with the inhibitor and increased with the agonist, thereby suggesting that the co-mitogenic effect of ET-1 is mainly via the activation of ETA receptors, with a small contribution by the ETB receptors in asthmatic BASM. Finally, pertussis toxin (PTX) pretreatment (25 and 50 ng/mL) showed that EGF and ET-1/EGF mitogenic and co-mitogenic signaling utilizes Gi/0-mediated transactivation by EGF and ET receptors, especially in asthmatic BASM, leading to the activation of Ras-ERK-PI3K pathways. Enhanced ERK and PI3K effects on proliferation suggested that these kinases modulate the co-mitogenic effect of ET-1 in asthmatic BASM. Enhanced cross-talk between ET and EGF receptors may be a potential mechanism contributing to airway remodeling in asthmatic BASM. ET-1 enhances the mitogenic effect of EGF predominantly via the ETA receptor in asthmatic BASM with the activation of Ras, ERK, and PI3K. The cross-talk mechanism between ET and EGF receptors may be a potential therapeutic target to prevent the progression of airway remodeling in ASM in patients with asthma.

6 December 2018 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
KHKoorosh Haghayeghi
Koorosh Haghayeghi
KHKatrine Hansen
Katrine Hansen
MQM. Ruhul Quddus
M. Ruhul Quddus